Drug Trial Radar · NCT05108922
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
Last checked: Nov 20, 2026Latest source record: Nov 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
148
Actual
Start
Nov 16, 2021
Primary completion
Sep 9, 2022
Study completion Sep 19, 2023
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Nov 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare donanemab to aducanumab on brain amyloid plaque clearance in participants with early symptomatic Alzheimer's Disease (AD).
Conditions
- Mild Cognitive Impairment (MCI)
- Alzheimer Disease
Interventions
DonanemabDrug
Participants received 700 milligram (mg) donanemab administered by intravenous (IV) infusion every 4 weeks (Q4W) for first three doses and then 1400 mg IV Q4W.
AducanumabDrug
Participants received aducanumab administered by IV infusion per US label (prescribing information/routine clinical practice).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus AducanumabTime frame: 6 Months
- Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus AducanumabTime frame: 6 Months
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Neurology Center of North Orange County
Fullerton, California
Irvine Clinical Research
Irvine, California
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California
Institute for Neurodegenerative Disorders
New Haven, Connecticut
JEM Research Institute
Atlantis, Florida
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Charter Research - Lady Lake
Lady Lake, Florida
ClinCloud - Maitland
Maitland, Florida
ClinCloud - Viera
Melbourne, Florida
Merritt Island Medical Research, LLC
Merritt Island, Florida
Optimus U Corporation
Miami, Florida
Brainstorm Research
Miami, Florida
Brain Matters Research
Stuart, Florida
Axiom Clinical Research of Florida
Tampa, Florida
Conquest Research
Winter Park, Florida
Columbus Memory Center, PC
Columbus, Georgia
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana
Donald S. Marks M.D., P.C.
Plymouth, Massachusetts
Adams Clinical
Watertown, Massachusetts
Clinical Research Professionals
Chesterfield, Missouri
Las Vegas Medical Research
Las Vegas, Nevada
The Cognitive and Research Center of New Jersey
Springfield, New Jersey
Advanced Memory Research Institute of New Jersey
Toms River, New Jersey
Neurology Diagnostics, Inc.
Dayton, Ohio
Abington Neurological Associates, Ltd.
Abington, Pennsylvania
The Clinical Trial Center, LLC
Jenkintown, Pennsylvania
Kerwin Medical Center
Dallas, Texas
National Clinical Research, Inc
Richmond, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.